Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
11 January 2021 | Story Thabo Kessah | Photo Supplied
The new book that Dr Tshepo Moloi has co-edited puts a spotlight on liberation struggle radios.
Dr Tshepo Moloi from the Qwaqwa Campus Department of History is the co-editor of a new book called Guerrilla Radios in Southern Africa: Broadcasters, Technology, Propaganda Wars, and the Armed Struggle.
This book is a collection of eleven essays on the histories of the radios attached to the armed wings of the liberation movements in the region. “This book is a shift from a parochial approach, which tended to analyse guerrilla radios within the framework of the nation state. It focuses on the experiences of the broadcasters and listeners during the era of the armed struggle. Using archival sources such as sound recordings of the guerrilla radio stations, together with interviews conducted with former broadcasters and listeners, the essays contained in this volume ask complex questions about the social histories of these stations,” said Dr Moloi.
Dr Moloi added that the essays explore the workings of propaganda and counter-propaganda and probe the effects that the radios had on the activists and supporters of the liberation movements – and, on the other hand, on the colonial counter-insurgency projects. They examine the relationships that these radios have forged at their multiple sites of operation in host countries, and also look at international solidarity and support, specifically for radio broadcasting initiatives. 
Role played by guerrilla radio
“Our volume pushes the frontiers of knowledge production beyond exploration of broadcast content towards a more nuanced conception of radio as a medium formed by social and political processes. Guerrilla radio broadcasting, we argue, became a very powerful technology for disseminating insurgent propaganda messages of the liberation movements and for mobilising African workers, peasants, students and youth in the struggle against white minority domination in the entire region. From Angola to Mozambique, and from Zimbabwe to Namibia through to South Africa, the modern technology of radio has provided the liberation movements in exile with a platform for an aural or sonic presence among the followers of the liberation movements back home. It has become an effective instrument for propagating the ideologies of the liberation movements, as well as for countering the propaganda messages of the oppressive white minority regimes,” he added.
Conceptualisation of the book
He also revealed the thinking behind the book. “The concept arose from the realisation that despite the explosion of research on liberation struggles in Southern Africa, such as memoirs, biographies, and autobiographies of prominent leaders of the movements, as well as a scattering of (auto)biographies of the foot soldiers, there remained a dearth of studies on the media that the liberation movements employed, particularly radio.”
Other editors are Sekibakiba Peter Lekgoathi, a professor of History at Wits University and Prof Alda Romão Saúte Saíde from Pedagogic University in Maputo, Mozambique. The project was funded by the National Institute for the Humanities and Social Sciences’ (NIHSS) Catalytic Research Project.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept